logo-loader
viewITUS Corp

ITUS Corporation shares up on Anixa Diagnostics news

ITUS Corporation revealed positive news from its diagnostics subsidiary, whose platform has been used to successfully detect lung cancer.

lungsCOPD.jpg
Anixa Diagnostics Corporation has successfully shown that its Cchek early cancer detection platform can be used to identify the presence of lung cancer, the group told investors....

ITUS Corporation (NASDAQ:ITUS) revealed positive news from its diagnostics subsidiary, whose platform has been used to successfully detect lung cancer.

Anixa Diagnostics Corporation has successfully shown that its Cchek early cancer detection platform can be used to identify the presence of lung cancer, the group told investors.

ITUS funds, develops, acquires, and licenses emerging technologies in areas such as biotechnology.

Anixa will now expand its ongoing biomarker study to include additional lung cancer samples. It comes after the group previously announced results from the study with breast cancer patients. 

Lung cancer is the leading cause of cancer death in the US, accounting for around 27% of all cancer related deaths, while breast cancer is the second leading cause.

Dr Amit Kumar, ITUS's executive chairman and Anixa's chief executive, said: "The most common method currently used for lung cancer screening is low dose computer tomography (LDCT), an often ineffective approach that generates numerous false positive results.

"To verify the results of LDCT, a biopsy is often utilised, requiring one of three procedures: a needle is inserted through the chest and into the lung to remove tissue; surgery through the chest wall between the ribs; or a bronchoscope inserted through the mouth or nose enabling removal of lung tissue.

"All of these techniques are extremely painful and costly. With further study and validation of our technology, our hope is to reduce the number of traditional lung biopsies."

Anixa is working with the Wistar Institute, at the campus of the University of Pennsylvania to develop a platform to launch non-invasive, highly accurate, cost effective cancer screening blood tests.

ITUS shares added 2.09% in New York to US$2.93.

Quick facts: ITUS Corp

Price: - -

NASDAQ:ITUS
Market: NASDAQ
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Preveceutical announces successful preliminary evaluation of...

Preveceutical (CSE:PREV-OTCQB: PRVCF) President Mak Jawadeker joined Steve Darling from Proactive Vancouver on Skype to discuss the company successfully completing the design, synthesis and preliminary evaluation of key peptides from its scorpion venom-derived peptide research and development...

2 days, 3 hours ago

2 min read